Updated: Nov 30, 2007
Rud syndrome, previously considered a rare recessive disorder marked by ichthyosis, hypogonadism, mental retardation, epilepsy, and dwarfism, is now classified as an ichthyosis. The contemporary ichthyosis classification reassigns it as a neuroichthyosis with cutaneous findings most similar to those observed in X-linked recessive ichthyosis, rather than a distinct clinical entity. Although ichthyosis and hypogonadism are the predominant features, neurologic deficits vary, suggesting genetic heterogeneity.
The pathophysiology of Rud syndrome is unknown. Defects in steroid sulfatase and Kallmann loci on the X chromosome have been identified; however, these defects were not tested in most of the earlier cases. Cases suggestive of an autosomal recessive inheritance pattern have also been reported.
The prevalence is rare worldwide.
Mortality and morbidity depend on the presence and the severity of associated findings.
No racial predilection is known.
Cases in which steroid sulfatase deficiency has been identified involved boys; however, overall, no male predilection is apparent, as anticipated by an X-linked recessive genodermatosis. This observation could be explained by the fact that a defect in an autosomal recessive gene may also be present (some cases suggestive of this inheritance pattern have been reported) or that such heterogeneity of clinical and genetic findings exists and some patients who are thought to have Rud syndrome really have different disorders manifesting with clinical changes similar to those of Rud syndrome.
The disease manifests with clinical signs and symptoms at birth or shortly thereafter.
Ichthyosis Vulgaris, Hereditary and
Acquired
Ichthyosis, X-Linked
Pituitary hypogonadism
Anosmia
Histologic findings may include nonspecific changes demonstrated by light and electron microscopy.
Surgical therapy of associated ophthalmologic problems may be indicated.
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
These agents promote shedding of hyperkeratotic skin. They are modifiers of keratinocyte adhesion, differentiation, and proliferation.
Contains lactic acid, an alpha hydroxy acid with keratolytic action. Comes in 12% and 5% strengths. The 12% concentration may cause irritation on the face. Causes disadhesion of corneocytes.
Apply topically to lesion or liberally to all affected areas bid for xerosis or other dry skin conditions
Apply as in adults
None reported
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
May sting or cause pain if applied on broken skin; the 12% concentration may cause irritation with erythema, burning, and peeling if applied to the face
Alpha hydroxy acid with keratolytic action.
Apply to affected areas prn
Apply as in adults
None reported
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
May sting or cause pain if applied on broken skin; for external use only
Promotes hydration and removal of excess keratin in conditions of hyperkeratosis. Available in 10-40% concentrations.
Apply to affected areas prn
Apply as in adults
May decrease effects of lithium
Documented hypersensitivity; severely impaired renal function; active intracranial bleeding; marked dehydration; frank liver failure; infusion into lower extremity veins in elderly patients may cause phlebitis and thrombosis
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Do not use if intracranial bleeding is present, unless prior to surgical intervention to control hemorrhage (reduction of brain edema by urea may result in reactivation of intracranial bleeding); may increase risk of venous thrombosis and hemoglobinuria in patients with hypothermia; caution in renal impairment
Andria G, Ballabio A, Parenti G, Di Maio S, Piccirillo A. Steroid sulphatase deficiency is present in patients with the syndrome 'ichthyosis and male hypogonadism' and with 'Rud syndrome'. J Inherit Metab Dis. 1984;7 Suppl 2:159-60. [Medline].
Kaufman LM. A syndrome of retinitis pigmentosa, congenital ichthyosis, hypergonadotropic hypogonadism, small stature, mental retardation, cranial dysmorphism, and abnormal electroencephalogram. Ophthalmic Genet. Jun 1998;19(2):69-79. [Medline].
Larbrisseau A, Carpenter S. Rud syndrome: congenital ichthyosis, hypogonadism, mental retardation, retinitis pigmentosa and hypertrophic polyneuropathy. Neuropediatrics. May 1982;13(2):95-8. [Medline].
Maldonado RR, Tamayo L, Carnevale A. Neuroichthyosis with hypogonadism (Rud's syndrome). Int J Dermatol. Jun 1975;14(5):347-52. [Medline].
Marxmiller J, Trenkle I, Ashwal S. Rud syndrome revisited: ichthyosis, mental retardation, epilepsy and hypogonadism. Dev Med Child Neurol. Jun 1985;27(3):335-43. [Medline].
Münke M, Kruse K, Goos M, Ropers HH, Tolksdorf M. Genetic heterogeneity of the ichthyosis, hypogonadism, mental retardation, and epilepsy syndrome. Clinical and biochemical investigations on two patients with Rud syndrome and review of the literature. Eur J Pediatr. Oct 1983;141(1):8-13. [Medline].
Stoll C, Eyer D. A syndrome of congenital ichthyosis, hypogonadism, small stature, facial dysmorphism, scoliosis and myogenic dystrophy. Ann Genet. 1999;42(1):45-50. [Medline].
Sybert VP. Ichthyosis with hypogonadism. In: Genetic Skin Disorders. ed. New York, NY: Oxford University Press; 1997:114-5.
Tercedor J, García A. [Keratotic neurocutaneous syndromes]. Rev Neurol. Sep 1997;25 Suppl 3:S238-42. [Medline].
Kuniba H, Egashira M, Motomura H, Motomura K, Kondoh T. [Rud syndrome]. Nippon Rinsho. Sep 28 2006;Suppl 3:485-7. [Medline].
ichthyosis with hypogonadism, neuroichthyosis, ichthyosis, hypogonadism, mental retardation, epilepsy, dwarfism
Suguru Imaeda, MD, Chief of Dermatology, Yale University Health Services; Chief of Dermatology, West Haven Veterans Affairs Medical Center; Assistant Professor, Department of Dermatology, Yale University School of Medicine
Suguru Imaeda, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Connecticut State Medical Society, Sigma Xi, and Society for Investigative Dermatology
Disclosure: Nothing to disclose.
Mark A Crowe, MD, Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine
Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society
Disclosure: Nothing to disclose.
Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.
Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.
Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.
William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System
William D James, MD is a member of the following medical societies: American Academy of Dermatology and Society for Investigative Dermatology
Disclosure: elsevier Royalty Other
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)